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Therapeutic faecal microbiota transplantation
controls intestinal inﬂammation through
IL10 secretion by immune cells
Claudia Burrello 1,2, Federica Garavaglia1, Fulvia Milena Cribiù3, Giulia Ercoli3, Gianluca Lopez3,
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Alteration of the gut microbiota has been associated with different gastrointestinal disorders.
Normobiosis restoration by faecal microbiota transplantation (FMT) is considered a pro-
mising therapeutic approach, even if the mechanisms underlying its efﬁcacy are at present
largely unknown. Here we sought to elucidate the functional effects of therapeutic FMT
administration during experimental colitis on innate and adaptive immune responses in the
intestinal mucosa. We show that therapeutic FMT reduces colonic inﬂammation and initiates
the restoration of intestinal homeostasis through the simultaneous activation of different
immune-mediated pathways, ultimately leading to IL-10 production by innate and adaptive
immune cells, including CD4+ T cells, iNKT cells and Antigen Presenting Cells (APC), and
reduces the ability of dendritic cells, monocytes and macrophages to present MHCII-
dependent bacterial antigens to colonic T cells. These results demonstrate the capability of
FMT to therapeutically control intestinal experimental colitis and poses FMT as a valuable
therapeutic option in immune-related pathologies.
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The gut mucosa constitutes a unique environment exposedto more than 1014 commensal bacteria, which establish amutualistic relationship with the host, providing metabolic
functions and contributing to shape the immune system1.
Maintenance of intestinal homeostasis requires several methods
to physically conﬁne commensal bacteria to the intestinal lumen,
while keeping the full capability to control colonization by
pathogenic bacteria1. Variations of this equilibrium induce the
recruitment and expansion of several immune cell types con-
tributing to initiate and propagate intestinal inﬂammation, or to
restore homeostasis by activating tolerogenic mechanisms2.
Alteration in the composition of the gut microbiota (dysbiosis)
has been associated with a wide range of gastrointestinal diseases,
including recurrent C. difﬁcile infection (CDI)3, inﬂammatory
bowel diseases (IBD, Crohn’s disease, CD, and Ulcerative colitis,
UC)4,5 and colorectal cancer (CRC)6.
Current theories suggest that IBD onset is secondary to an
exaggerated reaction of gut-associated lymphoid tissue against the
luminal microbiota7. Whether this is a primary defect or it is
secondary to intestinal dysbiosis is still debated. Indeed, a reduced
biodiversity in both mucus-associated and faecal bacterial com-
munities has been observed both in IBD patients and in their ﬁrst
degree relatives4,8,9. Moreover, IBD patients showed reduced
diversity of their gut microbiome, expansion of pro-inﬂammatory
bacteria like Enterobacteriaceae and Fusobacteriaceae and deple-
tion of phyla with anti-inﬂammatory functional properties such
as Firmicutes10. Additionally, changes in mucus-associated
microbiota have been observed in the ileal mucosa of children
with treatment-naïve IBD, independently from intestinal
inﬂammation4. These observations suggest that intestinal dys-
biosis may be causally related and might precede mucosal
inﬂammation in IBD patients. This has also been conﬁrmed by
the induction of experimental inﬂammation upon transfer of
dysbiotic microbiota or single commensal bacterial species in
germ-free mice11.
Intestinal epithelial damage has been proposed to be a key
event favouring bacteria translocation out of the intestinal lumen,
thus facilitating the recognition of antigens derived from the
dysbiotic microﬂora by pathogenic T cells in IBD patients7. A
complex physical barrier composed by a monolayer of polarized
epithelial cells has been developed to avoid exposure to the
intestinal microbiome12. Additionally, to prevent the bacterial
access to epithelial cells, mucous layers of different densities line
on top of the epithelium. Other host’s cellular components con-
tribute to homeostasis maintenance through the secretion of
antimicrobial peptides (AMPs)12.
Manipulation of the intestinal microbiome is becoming a
therapeutic option in several gastrointestinal disorders13. Faecal
microbiota transplantation (FMT), i.e. the infusion of healthy
donor faeces in the gut of a recipient to treat a disorder associated
with microbiota alterations, is receiving great consideration
thanks to its effectiveness against refractory and recurrent
CDI14,15. Increasing evidences from recent Randomized Clinical
Trials (RCTs) are also supporting the possibility to utilise FMT to
treat mild-to-moderate UC patients16–18. Despite its recent suc-
cesses, it is still largely unknown how FMT functionally mod-
ulates the intestinal immune system. Very limited data are
available on the therapeutic re-equilibration of the gut microbiota
in murine models of intestinal inﬂammation19,20.
Since the intestinal immune system is sensitive to variations of
luminal and mucus-associated bacteria, we postulated that ther-
apeutic FMT administered during intestinal inﬂammation might
directly modulate both innate and adaptive mucosal immune
responses towards the control of intestinal inﬂammation. Given
the predominant role of CD4+ T cells in orchestrating IBD-
related inﬂammatory processes21, largely due to their
differentiation into IFNγ/IL-17-secreting effector subtypes, we
focused our primary analysis on the functional variations
occurring in these cell populations upon FMT. The effect of
microbiota alterations during colitis induction and upon FMT
treatment in colitogenic mice was additionally assessed on
iNKT cells, a subset of αβ-T cells recognizing both self- and
microbial-derived glycolipids22,23 and heavily inﬂuenced by
bacterial-derived antigens in early life24,25. We also recently
showed that colonic iNKT cells are sensitive to microbiota
alterations occurring after short term antibiotic treatment26. To
selectively track this rare cell subset, we took advantage of a novel
reporter mouse strain, the CXCR6EGFP mouse27.
Here we demonstrate that therapeutic administration of FMT
during experimental colitis exerts beneﬁcial effects, which are
associated to the simultaneous activation of several anti-
inﬂammatory pathways. Upon FMT, variations in the intestinal
ecology towards IL-10-inducing microbial communities and the
production of tolerogenic IL-10 by mucosal innate and adaptive
cell subsets altogether concur to resolve the inﬂammation.
Results
Therapeutic FMT reduces inﬂammation in DSS-induced coli-
tis. CXCR6-EGFP/+ mice27 are susceptible to DSS-induced colitis
(Supplementary Fig. 1) and can be used to track intestinal CD4+
T cell subsets, including the relatively rare iNKT cells (Supple-
mentary Fig. 2), under homeostatic conditions26 and during
experimental intestinal inﬂammation.
Upon establishment of DSS-induced acute colitis, the func-
tional effects of therapeutic FMT were evaluated. Mucus and
faeces derived from normobiotic mice were collected and
microbiota transfer was performed in colitic mice by oral gavage
for 3 consecutive days according to the scheme described in
Fig. 1a. At sacriﬁce, FMT-treated mice showed reduced signs of
intestinal inﬂammation, as indicated by decreased weight loss
(Fig. 1b) and increased colonic length (Fig. 1c and Supplementary
Fig. 3a). These effects were associated to an amelioration of the
intestinal inﬂammation measured by the histological score upon
FMT (Fig. 1d, e and Supplementary Fig. 3b). Moreover, in
agreement with previously published reports19, FMT reduced the
expression of the pro-inﬂammatory Il1β (Fig. 1f and Supplemen-
tary Fig. 3c) in the colonic mucosa.
To evaluate whether FMT might exert protective effects on gut
barrier functions, the colonic expression of antimicrobial peptides
and mucins was also tested (Fig. 1g, h). The expression of the
tight junction protein Zo-1 was not affected upon FMT treatment
in the colons of colitic mice (Supplementary Fig. 3d). On the
contrary, Camp and S100A8, two antimicrobial peptides playing
anti-inﬂammatory roles during acute intestinal inﬂammation28
were upregulated upon FMT administration (Fig. 1g). Similarly, a
tendency toward upregulation of Muc1 and Muc4, two mucins
exerting anti-inﬂammatory functions in response to pathogens29,
and a downregulation of Muc3 were observed by FMT treatment
in acute DSS-colitis (Fig. 1h).
Thus, our results demonstrate that FMT therapeutic admin-
istration during experimental acute colitis ameliorates intestinal
inﬂammation.
FMT induces variations in the microbial communities. Next,
variations in the microbial communities in colitic mice treated or
not with FMT were evaluated. Fecal samples of DSS and DSS+
FMT mice were collected at day 11 post colitis induction and
subjected to microbiome proﬁling using 16S rRNA gene
sequencing on the Illumina MiSeq platform. An unweighted
UniFrac-based comparison of the microbiota isolated from
untreated, DSS and DSS+ FMT-treated recipient mice was
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performed (Fig. 2a and Supplementary ﬁgure 4a). Principle
component analysis (PCA) differentiated untreated mice from the
experimental groups (DSS and DSS+ FMT). The intestinal
microbiota of recipient mice receiving or not a FMT did not
macroscopically differ at sacriﬁce, possibly due to similar relative
abundances of the top 10 most abundant species among DSS and
DSS+ FMT-derived samples (Fig. 2b). Similarly, the microbiota
isolated from DSS-treated mice did not show a lower α-diversity
when compared to DSS+ FMT-derived microbiota, as reﬂected
by the Chao1 and Shannon indexes (Fig. 2c).
Nonetheless, a detailed phylogenetic analysis of the taxonomic
composition of the microbiome of colitic mice treated or not with
FMT showed that the reduced inﬂammatory conditions observed
upon FMT administration were associated, with variations in the
abundance of speciﬁc taxa, including Firmicutes and Verrucomi-
crobiae30,31. (Fig. 2d–f).
Signiﬁcant changes towards restoration of normobiosis were
detected among the less abundant families belonging to the
Firmicutes phylum in the DSS+ FMT–derived microbiota. For
instance, Clostridiaceae and Clostridiales, which were expanded in
colitic mice, were reduced upon FMT and returned to levels
comparable to those observed in untreated mice (Fig. 2e).
FMT-derived samples showed signiﬁcant increases of known
commensals used in probiotics preparations32, including Lacto-
bacillaceae and Streptococcus sp., and of the SCFA-producing taxa
Erysipelotrichaceae, Ruminococcaceae, Odoribacter and Olsenella
(Fig. 2f and Supp Fig. 4B), which are reported to be reduced in
IBD patients4,33.
Of note, metabolomic analysis showed an increased faecal
content of complex sugars including lactose and maltose in DSS-
treated mice, a possible consequence of impaired digestion or
defective intestinal absorption34, whose levels were normalized by
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Fig. 1 Therapeutic FMT ameliorates DSS-induced experimental colitis. a Schematic representation of FMT treatment during acute DSS experimental colitis.
b, c Weight loss (b) and colon length (c) of untreated (triangles and striped boxes), colitic (black dots and black boxes), or colitic mice treated with FMT
(white dots and white boxes). d, e H&E staining (scalebar 100 µm) and cumulative histological score of colon specimens obtained from DSS-treated and
FMT-treated mice; (e) Detailed histological evaluation of mice with decreased histological score (white boxes) compared to DSS-treated mice (black
boxes). f Colonic expression levels of Il1β in colitic (black boxes) and FMT-treated (white bars) mice. g, h Colonic expression levels of Camp, S100A8
(g) and Muc1, Muc3, Muc4 (h) in untreated (white boxes), DSS treated (black boxes) or DSS+ FMT-treated (gray boxes) mice. Statistical signiﬁcance was
calculated using a Mann–Whitney test for comparison within two groups or Kruskal–Wallis test with Dunn’s multiple comparison correction within more
than two groups. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 were regarded as statistically signiﬁcant. Outliers were detected with Grubb’s test. Non
parametric distributions were represented as median+ /- interquartile range. In Box and whiskers plots, centre line represents median; cross, represents
mean. In (b) UT n= 10, DSS n= 10, DSS+ FMT n= 10. In (c) UT n= 12, DSS n= 12, DSS+ FMT n= 14. In (d) UT n= 8, DSS n= 15, DSS+ FMT n= 19. In
(f–h) UT n= 5, DSS n= 6, DSS+ FMT n= 7
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FMT-treatment. Similarly, glutamic acid, a metabolite altered in
IBD patients35, decreased upon FMT while gluconic acid and
Dihydroxiacetone, involved in natural detoxiﬁcation activities36,
increased upon FMT (Fig. 2g, h).
Altogether, these ﬁndings suggest that the beneﬁcial effects of
FMT during intestinal inﬂammation are associated with a
reshufﬂing of the microbiota communities towards restoration
of functional normobiosis.
FMT effects rely on the presence of normobiotic ecologies.
Once documented the beneﬁcial effects of FMT, the impact of the
donor microbiota composition on the resolution of intestinal
inﬂammation was evaluated.
To do so, mucus and faecal samples were obtained from
normobiotic or dysbiotic mice, i.e from healthy mice left
untreated or treated for 7 days with DSS, and FMT was
performed in colitic mice as previously described in Fig. 1a.
Relevant differences between the two types of donors used for
FMT experiments were conﬁrmed by metagenomic analyses
(Fig. 3a, b and Supplementary ﬁg 5A). As previously shown31, the
microbiota of dysbiotic mice was characterized by a contraction
of Bacteroidales S24-7, Lachnospiraceae and Biﬁdobacteriaceae
and an expansion of Enterobacteriaceae and Bacteriaceae as
compared to that of normobiotic mice (Fig. 3a).
As a consequence, an amelioration of the intestinal inﬂamma-
tion was reported in mice receiving a normobiotic FMT but not
in those receiving a dysbiotic FMT, as demonstrated by an
increase in colon length (Fig. 3c) and a decrease, albeit not
signiﬁcant, in the expression levels of colonic pro-inﬂammatory
Il1b and Tnf (Fig. 3d).
Consistently, the microbial composition of recipient mice that
were transplanted with a dysbiotic FMT was also more similar to
that of DSS-treated mice, enriched in pathobionts such as E.Coli/
Shigella (Fig. 3e), while the microbiota of mice receiving a
normobiotic FMT were more similar to that of untreated mice,
enriched in protective SCFA-producing bacteria (Fig. 3e). Simi-
larly, metabolomic analysis of the faeces of recipient mice treated
with normobiotic FMT revealed the presence of metabolites
associated to scavenging of free radicals (d-glucunolactone)
and metals (gluconic acid)36, to the control of ROS
production and neutrophils activity (hydroxiphenillactic acid)
and chemotaxis (LPA)37, and to SCFA production (Valeric acid)38
(Fig. 3f).
Next, we evaluated if normobiotic donors of different origins
might be equally capable to control intestinal inﬂammation when
transplanted into colitic mice. Mucus and faecal samples were
isolated form age- and sex-matched C57Bl/6 mice obtained from
different sources, i.e. from two commercial animal vendors
(Charles River srl and Envigo srl) and from in-house bred C57Bl/
6 wild-type colony (IEO animal facility). Interestingly, the FMT
performed with the microbiota isolated from the different
normobiotic donors was equally capable to control intestinal
inﬂammation, as shown by similar colon length (Fig. 4a),
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DSS+ dFMT n= 7. In (e) UT n= 6, DSS n= 8, DSS+ nFMT n= 7, DSS+ dFMT n= 7. In (f) DSS n= 5, DSS+ nFMT n= 10, DSS+ dFMT n= 11
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histological score (4b) and expression of colonic pro-
inﬂammatory genes (Fig. 4c)
As previously observed11,39,40, donor mice sharing the same
genetic background, sex and age, but raised in different animal
facilities harbored a microbiota genetically similar, not identical,
(Fig. 4d, and Supplementary ﬁg 5b) but capable to perform
overlapping metabolic activities (Fig. 4e). In accordance to very
recent data41, 90 to 93% of the total taxa relative abundance of
normobiotic mice, regardless of its origin, was composed by a
similar core microbial ecology of Bacteroidales S24-7 (30-45%
among groups), Lachnospiraceae (28-38%), Lactobacillaceae
(6-15%), Ruminococcaceae (5-8%), Rikenellaceae (3−6%), Biﬁdo-
bacteriaceae (1–2%) and Erysipelotrichaeceae (1–5%), that in
dysbiotic mice accounted only for a total 75% (Fig. 4f). These taxa
have been functionally associated to homeostatic metabolic
activities, including SCFA production leading to Treg cells
differentiation and IL-10-production42-44. On the contrary, the
taxa expanded in dysbiotic mice accounting for a 25% of the total
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microbial ecology, which were either completely absent or present
in extremely low abundancies in normobiotic mice, were mostly
Enterobacteriaceae, Bactaeriaceae, Rhodospirillaceae, Streptococ-
caceae, which have been shown to be increased both in colitic
mice and IBD patients4,31(Fig. 4f)
Taken together, these data indicate that beneﬁcial effects of
FMT are strictly dependent on the graft composition, and that
only a healthy microbiota can ameliorate the intestinal
inﬂammation.
FMT inﬂuences colonic immune cells relative abundance.
Given the strict interdependence between intestinal immune
system and the host microbiota45, we next aimed to explore
immune pathways selectively modulated by FMT, We thus asked
if therapeutic FMT administration in colitic mice induced var-
iations in the frequencies and in the functional activities of the
immune cell colonic inﬁltrate. The presence of speciﬁc bacterial
strains in the gut has been linked to the differentiation and
expansion of conventional11 and unconventional25 CD4+ T cells.
An increase of iNKT cell frequency, but not absolute numbers,
(Fig. 5a) was observed in DSS-treated mice after FMT, while CD4
+ T cells were decreased both in frequency and numbers (Fig. 5a),
in line with their reduced proliferative capacity (Fig. 5b). Given
that iNKT cells isolated from FMT-treated and untreated mice
exhibited similar Ki67 expression (Fig. 5b), the increase of iNKT
cell percentages on total CD3+ lymphocytes was likely a con-
sequence of the overall reduction of CD4+ T cells rather than of
their expansion (Fig. 5b). On the contrary, colonic CD8+ T cells
frequency (Supplementary Fig. 6a) and phenotype (Fig. 5c) were
not affected by FMT-treatment.
Interestingly, we found that FMT treatment was able to reduce
the inﬂammation-driven expansion of the innate lymphocytes
ILC2 and ILC346,47 in the lamina propria of acute DSS-treated
mice (Supplementary Fig. 6b, c)
Antigen presenting cells (APC) and immune cells of myeloid
origin inﬁltrating the inﬂamed lamina propria have been shown
to contribute to sustain and propagate intestinal inﬂammation2.
Following therapeutic FMT, a reduction in F4/80+ macrophages
and CD11b+Ly6G+ neutrophils frequency (Fig. 5d) and partially
in absolute numbers (Fig. 5e) was observed. In contrast, CD19+B
cells and CD11c+dendritic cells were mostly unaffected (Fig. 5d,
e).
Further, several evidences suggest that mucosal T-helper cells
activation during intestinal inﬂammation depends on antigenic
stimulation2. After FMT, both the number of colonic MHC-II-
expressing professional APC, including dendritic cells and
macrophages, (Fig. 5f) and MHC-II expression levels on APC
(Fig. 5g) were strongly reduced, suggesting that FMT might
directly act on the antigen presenting capacity of professional
APC.
To note, similar ﬁndings were observed in the TNBS-induced
experimental colitis model (Supplementary Figure 7)
Taken together, these data indicate that therapeutic FMT exerts
a speciﬁc effect on inﬁltrating immune cells population frequency
and phenotype.
CD4+ T cells cytokine skewing requires antigen presentation.
We next evaluated if FMT administration might inﬂuence speciﬁc
immune cells functional activities that are directly correlated to
bacterial antigens presentation.
The faeces of untreated, DSS-treated and FMT-treated mice
were collected and used to stimulate in-vitro intestinal lamina
propria mononuclear cells (LPMC) freshly isolated from healthy
mice (Fig. 6a).
As observed in vivo, MHC-II levels on dendritic cells,
macrophages and monocytes were down-regulated upon
in vitro exposure to normal (untreated) or FMT-derived
microbiota (Fig. 6b). Similarly, the expression of CD86, a co-
stimulatory molecule critically involved in T cell stimulation, was
reduced on APC exposed to untreated or FMT-derived micro-
biota as compared to those exposed to the faeces of DSS-treated
mice (Supplementary Fig. 8a).
Cytokines produced by mucosal antigen presenting cells play a
pivotal role in the initiation and propagation of intestinal
inﬂammation, as in the maintenance of homeostasis48. To
evaluate the cytokine milieu generated upon exposure to FMT-
derived microbiota, we analysed the supernatants of stimulated
intestinal LPMC (Fig. 6c). Interestingly, LPMC exposed to FMT-
derived microbiota showed reduced levels of pro-inﬂammatory
cytokines, such as TNF, IL1β and IFNγ (Fig. 6c), which were
instead increased in the supernatants of LPMC exposed to DSS-
derived microbiota.
FMT-derived microbiota was also capable to differently skew
the cytokine proﬁle of antigen presenting cells (Fig. 6d, e). Indeed,
the frequency of pro-inﬂammatory TNF-producing intestinal
dendritic cells and macrophages was strongly reduced upon
exposure to FMT-derived microbiota (Fig. 6d). Conversely, FMT-
derived microbiota increased the frequency of IL-10-producing
intestinal dendritic cells and monocytes (Fig. 6e).
Correspondingly, CD4+ T cell expansion occurred only after
stimulation with DSS-derived, but not with normal or FMT-
derived microbiota (Fig. 6f). To note, FMT-derived microbiota
slightly increased the frequency of Foxp3+ Treg cells (Supple-
mentary Fig. 8b).
DSS-derived microbiota also induced a strong upregulation of
CD69 on intestinal CD4+ T cells, while untreated or FMT-
derived microbiota failed to do so (Fig. 6g). Likewise, only FMT-
derived microbiota signiﬁcantly increased IL-10 secretion by
CD4+ T cells, in an MHC-II dependent fashion (Fig. 6h).
Importantly, also IFNγ secretion was dependent on antigen
presentation (Fig. 6h).
Fig. 4 Similar ecologies from different FM donors elicit same beneﬁcial effects. a, b Colon length (a) and cumulative histological score (b) of DSS (black
boxes), DSS+ IEO-FMT (white boxes), DSS+ CR-FMT (dotted boxes) and DSS+ Envigo-FMT (striped boxes) treated mice. c Colonic expression of
Tnf and Il1b in DSS (black boxes), DSS+ IEO-FMT (white boxes), DSS+ CR-FMT (dotted boxes) and DSS+ Envigo-FMT (striped boxes) treated mice
d Comparison of relative abundancies of different taxa between Envigo- (outer chart), Charles River- (CR) (middle chart) or IEO-derived faecal microbiota.
e Partial Least square-discrimination analysis (PLSD-DA) on metabolomics data between Envigo- (blue), Charles River- (CR, green) or IEO (red)-derived
faecal microbiota. f Comparison of relative abundancies of different taxa between normobiotic-, IEO-, CR- Envigo- and dysbiotic-derived fecal microbiota.
Statistical signiﬁcance was calculated using a Mann–Whitney test for comparison within two groups or Kruskal–Wallis test with Dunn’s multiple
comparison correction within more than two groups. *P < 0.05, **P < 0.01, ***P < 0.001 were regarded as statistically signiﬁcant. Outliers were detected
with Grubb’s test. Non parametric distributions were represented as median+ /- interquartile range. In Box and whiskers plots, centre line represents
median; cross, represents mean; dots represent outliers. In (a–c) DSS n= 7, DSS+ IEO-FMT n= 10, DSS+ CR-FMT n= 10, DSS+ Envigo-FMT n= 10. In
(d, f) IEO-FMT n= 9, CR-FMT n= 10, Envigo-FMT n= 9, nFMT= 7, dFMT= 7. In (e) DSS n= 5, DSS+ IEO-FMT n= 6, DSS+ CR-FMT n= 5, DSS+
Envigo-FMT n= 5
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Taken together these data conﬁrm a crucial role for bacterial
antigen presentation in the tolerogenic skewing of innate and
adaptive colonic immune populations upon FMT treatment.
IL-10 critically contributes to FMT beneﬁcial effects. In vitro
experiments indicated that IL-10 production by intestinal
immune cells might be critically involved in the tolerogenic
mechanisms triggered by therapeutic FMT during experimental
colitis. We thus evaluated if these mechanisms occurred in vivo
upon FMT, and if IL-10 production by immune cells might be
responsible for the observed therapeutic effects of FMT.
Higher amounts of colonic IL-10 (Fig. 7a) as well as increased
frequencies of IL-10-producing APC (Fig. 7b, c) and CD4+ T and
iNKT cells (Fig. 7d) were observed in the colons of FMT-treated
mice as compared to DSS-treated mice. Interestingly, the
increased IL-10 secretion by T cells observed in FMT-treated
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Fig. 5 Therapeutic FMT modulates immune cell frequencies and phenotypes. a Representative dot plots (upper panels), frequencies and absolute numbers
(lower panels) of colonic CD4+ T cells and iNKT cells in DSS-treated (black bars) and FMT-treated (white bars) mice 11 days after starting DSS
administration. b Representative dot plots, (upper panels), frequencies and absolute numbers (lower panels) of Ki67-expressing colonic CD4+ T cells and
iNKT cells in DSS-treated (black bars) and FMT-treated (white bars) mice. c Representative dot plots, (upper panels), frequencies and absolute numbers
(lower panels) of Ki67 and CD107a- expressing colonic CD8+ T cells in DSS-treated (black bars) and FMT-treated (white bars) mice. d Representative dot
plots and frequency of dendritic cells (CD45.2+CD3-CD11c+), macrophages (CD45.2+CD3-F4/80+CD11b−), B cells (CD45.2+CD3−CD19+), neutrophils
(CD45.2+CD3−Ly6g+CD11b+) in DSS-treated (left panels) and FMT-treated (right panels) mice 11 days after starting DSS administration. e Absolute
numbers of colonic dendritic cells, macrophages, B cells, neutrophils in DSS-treated (black boxes) and DSS+ FMT-treated (white boxes). f Absolute
numbers of MHC-II expressing colonic dendritic cells, macrophages, B cells and neutrophils in DSS (white boxes) and DSS+ FMT-treated (black boxes)
mice. g Representative histograms of MHC-II expression and cumulative Mean ﬂuorescence intensity (MFI) on colonic dendritic cells, macrophages, B
cells, neutrophils in DSS (black boxes) and DSS+ FMT (white boxes) treated mice. Statistical signiﬁcance was calculated using a Mann–Whitney test for
comparison within two groups or Kruskal–Wallis test with Dunn’s multiple comparison correction within more than two groups. *P < 0.05, **P < 0.01, ***P
< 0.001 were regarded as statistically signiﬁcant. Outliers were detected with Grubb’s test. Non parametric distributions were represented as median+ /-
interquartile range. In Box and whiskers plots, centre line represents median; cross, represents mean; dots represent outliers. In (a–c) DSS n= 12, DSS+
FMT n= 12. In (d–g) DSS n= 16, DSS+ FMT n= 16
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test for comparison within two groups or Kruskal–Wallis test with Dunn’s multiple comparison correction within more than two groups. *P < 0.05, **P <
0.01, ***P < 0.001 were regarded as statistically signiﬁcant. Outliers were detected with Grubb’s test. Non parametric distributions were represented as
median+ /− interquartile range. In Box and whiskers plots, centre line represents median; cross, represents mean; dots represent outliers. In all panels UT
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NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07359-8 ARTICLE
NATURE COMMUNICATIONS |          (2018) 9:5184 | https://doi.org/10.1038/s41467-018-07359-8 | www.nature.com/naturecommunications 9
DS
S
 D
SS
+ 
FM
T  
   
   
   
   
   
IL
-1
0,
 n
g
(o
n 
10
0 
μg
 o
f p
ro
te
in
 ly
sa
te
)
0 10000 0
2
4
6
8
IL-10 IL-17 IL-22 IL-10 IL-17 IL-22
E
ve
tn
s,
 r
el
at
iv
e 
to
 m
od
e
Isotype
DSS
IL
-1
0,
 M
F
I o
n 
C
D
3–
 L
in
+
*
30
60
1250
1500
IL
-1
0,
 %
 o
n 
C
D
3–
 L
in
+
DSS + FMT
DSS + FMT
IL-10
DSS
DSS
0
35
70
0
50
100
DSS + FMT
e f g
h i
   
   
 C
yt
ok
in
es
,
 %
 o
f C
D
4+
 T
 c
el
ls *
*
*
C
yt
ok
in
es
,
 %
 o
f i
N
K
T
 c
el
ls
0
4.5
9
70
80
90
100
110
IFNγ IFNγ
0 8 9 10
S
ta
rt
 D
S
S
S
to
p 
D
S
S
F
M
T
 (
M
uc
us
)
F
M
T
 (
F
ae
ce
s)
α
IL
-1
0R
α
IL
-1
0R
α
IL
-1
0R
α
IL
-1
0R
F
M
T
 (
F
ae
ce
s)
S
ac
rif
ic
e
117
Un
tre
at
ed
DS
S
DS
S 
+ 
FM
T
DS
S 
+ 
αI
L-
10
R
DS
S 
+ 
FM
T 
+ 
αI
L-
10
R
DS
S 
+ 
FM
T 
+ 
iso
typ
e
C
ol
on
 le
ng
th
 (
cm
)
* *
*
*
**
S
ta
rt
in
g 
w
ei
gh
t (
%
)
120
0
1
2
0 0
4
8
Days
***
***
***** * *
0 3 6 9 12
Untreated
DSS
DSS + αIL10R
DSS + FMT
DSS + FMT + αIL10R
DSS + FMT + isotype
DSS
DSS + αIL10R
DSS + FMT
DSS + FMT + αIL10R
DSS + FMT + isotype
DSS
K
i6
7+
 C
D
4+
 T
 c
el
ls
,
ab
so
lu
te
 n
um
be
rs
 (
×
10
3 ) *
* *
0
4
8
K
i6
7+
 iN
K
T
 c
el
ls
,
 a
bs
ol
ut
e 
nu
m
be
rs
 (
×
10
3 )
ns
ns
DSS + αIL10R
DSS + FMT
DSS + FMT + αIL10R
DSS + FMT + isotype
Tn
f, 
re
la
tiv
e 
to
 R
pl
32
* *
Ifn
g,
 re
la
tiv
e 
to
 R
pl
32
**
***
*
*
0.2
0.4
Il1
b,
 re
la
tiv
e 
to
 R
pl
32
0
0.5
1
a b c
d
Fig. 7 IL-10 contributes to FMT beneﬁcial therapeutic effects. a IL-10 colonic expression in DSS-(black boxes) and DSS+ FMT-(white boxes) treated mice.
b, c Representative histograms of IL-10 expression (b) and cumulative Mean ﬂuorescence intensity (MFI) (c, left panel) and frequency (c, right panel) of IL-
10-producing colonic professional APC (CD45+CD3−MHC-II+) in DSS (black boxes) and DSS+ FMT (white boxes) treated mice. d Summary of cytokines
secreted by colonic CD4+ T cells and iNKT cells in DSS-treated (black boxes) and FMT-treated (white boxes) mice 11 days after starting DSS
administration. e Schematic representation of the experiment. f, g Colon length (f) and weight loss (g) of untreated mice (white dotted boxes/open
circles), or receiving DSS (black boxes/black symbols), or DSS+ FMT (white boxes/white square symbols) or DSS+ αIL-10R (green boxes/green
symbols), or DSS+ FMT+ αIL-10R (blue boxes and blue symbols) or mice receiving DSS+ FMT+ αIL-10R isotype antibody (red boxes/red symbols).
h Colonic expression of Tnf, Ifnγ and IL1β in DSS (black boxes), DSS+ FMT (white boxes), DSS+ αIL-10R (blue boxes), DSS+ FMT+ αIL-10R- (green
boxes) and DSS+ FMT+ αIL-10R-isotype-antibody-treated mice (red boxes). i Absolute numbers of KI67 expressing colonic CD4+ T cells (left panels)
and iNKT cells (right panels) in DSS (black boxes), DSS+ FMT (white boxes), DSS+ αIL-10R (blue boxes), DSS+ FMT+ αIL-10R (green boxes) and DSS
+ FMT+ αIL-10R isotype antibody (red boxes). Statistical signiﬁcance was calculated using a Mann–Whitney test for comparison within two groups or
Kruskal–Wallis test with Dunn’s multiple comparison correction within more than two groups. *P < 0.05, **P < 0.01, ***P < 0.001 were regarded as
statistically signiﬁcant. Outliers were detected with Grubb’s test. Non parametric distributions were represented as median+ /- interquartile range. In Box
and whiskers plots, centre line represents median; cross, represents mean; dots represent outliers. In (a) DSS n= 15,DSS+ FMT n= 26. In (b–d) DSS n=
14,DSS+ FMT n= 17. In (e–i) DSS, DSS+ FMT n= 4; DSS+ αIL-10R,DSS+ FMT+ αIL-10R n= 5, DSS+ FMT+ isotype n= 3
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mice normalised upon inﬂammation resolution (Supplementary
Fig. 9b). To test the contribution of IL-10 on the anti-
inﬂammatory properties of FMT, DSS-treated mice were
administered FMT concomitantly to IL-10 receptor (IL-10R)
blockade (Fig. 7e). Inhibition of the tolerogenic functions of IL-10
on IL-10R expressing cells, such as antigen presenting cells
(APC), T cells and epithelial cells49, hampered FMT protective
effects as shown by reduced colon length (Fig. 7f), increased
weight loss (Fig. 7g) and higher colonic expression of Tnf, Ifnγ
and Il1β (Fig. 7h). These effects were not observed when IL-10R
was blocked in colitic mice without a concomitant FMT
administration, suggesting a direct contribution of the microﬂora
in the IL-10-mediated control of inﬂammation. As expected, IL-
10R blockade reverted the inhibition of CD4+ T cells prolifera-
tion occurring upon FMT (Fig. 7i). IL-10R blockade also affected
IL-10 production by T and iNKT cells, possibly through a
feedback regulatory loop (Supplementary Fig 9c).
Protective bacteria selective elimination impairs FMT effect.
To further correlate the gut microbiota composition to the
induction of protective immune-mediated functions during
intestinal inﬂammation, therapeutic FMT was performed with
mucus and faeces isolated from mice previously pre-treated for
two weeks with different antibiotics targeting either Gram-
positive organisms (vancomycin), Gram- negative bacteria
(streptomycin), strict anaerobes (metronidazole) or having a
broad spectrum bacterial depletion capability (ABX) (Fig. 8a)50.
The taxonomic composition of the different donor microbiota
was analysed by 16 S rRNA gene sequencing before administra-
tion to colitic mice. As expected, the α-diversity in antibiotic-
treated samples was lower as compared to those derived from
normobiotic samples (Fig. 8b), evidence conﬁrmed also by plating
of the faecal material in aerobic and anaerobic conditions
(Fig. 8c).
The detailed phylogenetic analysis of the taxonomic composi-
tion highlighted a relevant dysbiosis in the antibiotic- treated
donor samples as compared to the untreated ones (Fig. 8d, e). In
particular, metronidazole treatment favored the selective persis-
tence of Lactobacillaceae, Biﬁdobacteriaceae and Erysipelotricha-
ceae, as well as of Ruminococcacceae and Bacteroidales S24-7,
families belonging to the protective normobiotic microbial
ecologies31 previously described in Fig. 4. On the contrary,
pathobionts such as Christensenellaceae, Burkholderiales, Lister-
iaceae and Gastranaerophilales signiﬁcantly emerged in
Vancomycin-treated samples at the expenses of the above-
mentioned protective families. Streptomycin-treatment, instead,
favoured a limited presence of Erysipelotrichaceae and Rumino-
coccaceae while not expanding pathobionts, but rather allowing
the survival of families whose function could be protective or
detrimental according to the context1,51. As a proof of concept,
the microbial population of broad spectrum antibiotic-treated
mice was completely depleted, as conﬁrmed by the plating of their
faecal material (Fig. 8c).
Of note, FMT performed with metronidazole-treated micro-
biota retained a full capability to control intestinal inﬂammation
(Fig. 8f, g and Supplementary Fig 10). Importantly, this was
associated with a selective increased production of IL-10 by
colonic APC (Fig. 8h), as to conﬁrm the previously suggested IL-
10 promoting activity of Lactobacillaceae and
Biﬁdobacteriaceae52.
In conclusion, our data show that the gut microbiome
modiﬁcations after FMT exert a profound impact on the mucosal
immune system. The composition of the microbial ecology
transferred by FMT is pivotal to its beneﬁcial anti-inﬂammatory
effects by supporting changes in immune cell frequencies, the
reduction of colonic ifnγ and il1β, the increase in antimicrobial
peptides and mucins, and the decrease of bacterial antigen
presentation by APC. Most importantly, normobiotic FMT
induces the skewing of innate and adaptive immune cells toward
a tolerogenic IL-10 secreting cytokine proﬁle that, altogether,
concur to restore intestinal homeostasis (Fig. 9).
Discussion
FMT is becoming the ﬁrst-line therapy in antibiotic resistant
recurrent CDI14,15. However, its therapeutic application to other
gastrointestinal diseases is at the very beginning and data on its
mechanism of action during intestinal inﬂammation are still
scarce. While it is known that restoration of normobiosis corre-
lates with clinical remission in successful trials involving UC
patients16–18, it is still unclear whether FMT might have an effect
on the immune system. To date, data in BALB/c mice suggest that
FMT can induce CD4+CD25+ regulatory T cells and reduce
colonic expression of Il1β and Ifnγ19.
In our study, we show for the ﬁrst time that the manipulation
of the gut microbiota by FMT induces variations in both innate
and adaptive immune cell frequencies and cytokine proﬁles and
that this correlates with a general amelioration of the inﬂam-
matory status in colitic animals. Moreover, analyses of the gut
microbiota in our model showed that 3 days of therapeutic FMT
are sufﬁcient to introduce modiﬁcations in the dysbiotic micro-
biota, with a relevant change in the relative proportions of Fir-
micutes. These results are in agreement with ﬁndings from
successful FMT clinical trials on UC patients and from animal
models of intestinal inﬂammation. In particular, data in UC
patients showed that clinical remission correlated with stable
modiﬁcations of the gut microbiota towards functional normo-
biosis restoration16–18 and that this shift in intestinal microbial
ecology was sufﬁcient to trigger reduction of inﬂammatory genes
such as ifnγ, il1β and tnf53. Further, in IBD patients and in animal
models of intestinal inﬂammation4,33,54 changes in the levels of
Erysipelotrichaceae and Lactobacillacee have been described.
Interestingly, we found that these taxa were also similarly altered
in DSS-treated mice, and their abundances were restored upon
therapeutically successful FMT.
It is now acknowledged that the gut microbiota composition
is heavily inﬂuenced by age, gender, genotype, diet and envir-
onmental factors55. In this context, animal models are valuable
tools to study complex biological phenomena, such as those
occurring during intestinal inﬂammatory processes, while
controlling confounding variables. It also emerged from several
recent studies that different research institutions or commercial
vendors might harbour variations in the microbiological
environment39,40, leading to differences in microbiota compo-
sition. Here we showed that the microbiota derived from three
different sources were equally capable to control intestinal
inﬂammation in our experimental model, and this capability
was dependent on the presence of a core microbial ecology
composed by Bacteroidales S24-7, Lachnospiraceae, Lactoba-
cillaceae, Ruminococcaceae, Rikenellaceae, Biﬁdobacteriaceae
and Erysipelotrichaceae. As recently shown also in metabolic
diseases41 and in murine models of intestinal inﬂammation31,
this core ecology consists of bacteria from different phyla
sharing similar metabolic functions (i.e: SCFA production, Ph
control, free radicals scavenging) and, when maintained at a
certain population level, capable to create environmental con-
ditions sufﬁcient to inhibit the growth of pathogenic species/
pathobionts and support optimal host health.
A healthy gut environment, shaped by the presence of a healthy
functional microbial ecosystem, is thus fundamental to instruct
the immune system towards homeostasis.
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Several reports describe the pivotal role of T cells as key players
in the initiation and maintenance of intestinal inﬂammation. For
instance, we56 and others57,58 reported that IBD patients show
increased amounts of intestinal Th1, Th17 and Th1/17 cells
whose pathogenic role has been associated to the recognition of
bacterial antigens7,59,60. In addition to conventional CD4+
T cells, other T cell subsets, like iNKT cells, can secrete IL17A and
IFNγ in the gut and affect bacterial colonization of the intes-
tine20,61 but their role in intestinal inﬂammation is less well
deﬁned62.
In our study, in vitro stimulation of intestinal lamina propria
cells with faecal content from untreated, DSS or FMT-treated
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mice induced a different cytokine proﬁle in both innate and
adaptive immune cells, suggesting that the alterations in the
microbiota ecology during colitis and upon FMT are directly
linked to changes in the functional status of the mucosal immune
system.
Additionally, our data indicate that variations in the intestinal
microbial ecology are also capable to skew, both in vitro and
in vivo, the cytokine proﬁle of antigen presenting cells from pro-
inﬂammatory to tolerogenic45.
In particular, we show that in acute models of intestinal
inﬂammation, IL-10 secretion by APC and T cells upon FMT is
temporally linked to the resolution of inﬂammation, conﬁrming
a direct contribution of IL-10-mediated functional activities in
intestinal homeostasis63 also in the context of FMT. IL-10 is an
anti-inﬂammatory cytokine known to critically maintain
intestinal immune homeostasis64. IL-10-deﬁcient mice and
patients with genetic defects in the IL-10/IL-10R pathway
develop intestinal inﬂammation in the presence of a normal gut
microﬂora. Moreover, the presence of speciﬁc commensal
bacteria such as Lactobacilli and Biﬁdobacteria have been
directly associated to the secretion of tolerogenic IL-1052 and
has been implicated in the maintenance of intestinal home-
ostasis65. Several studies report that a probiotic preparation
(#VSL3) composed by a cocktail of eight strains of Lactobacilli
and Biﬁdobacteria is effective in controlling intestinal
inﬂammation32
Fig. 8 Antibiotic treatment selectively abolishes FMT beneﬁcial effects. a Schematic representation of the experiment. b Rarefaction curves showing
microbial richness (Chao1 index,top panel) and microbial richness and evenness (Shannon index,bottom panel). Black line, untreated-, red line ABXFMT-,
blue line Strepto FMT-, Green line Metro FMT-, Violet line Vanco FMT- derived samples. c Plating of faecal material derived from untreated, treated with
the antibiotic cocktail (ABX) or with streptomycin (Strepto), Metronidazole (Metro) or Vancomycin (Vanco) in aerobiosis (left) and anaerobiosis (right). d
Comparison of relative abundancies of different taxa between faecal microbiota obtained from normobiotic (outer chart) and Streptomycin-treated mice
(inner chart, left panel), or Metronidazole-treated (inner chart, middle panel) or Vancomycin-treated mice(inner chart, right panel). e Heat map comparing
the expression levels of the different taxa between faecal microbiota obtained from normobiotic, Streptomycin-, Metronidazole- or Vancomycin-treated
mice. f, g Colon length (f) and il1b colonic expression (g) in DSS-treated (black boxes), DSS+Untreated FMT (white boxes), DSS+ABX FMT (red boxes),
DSS+ Streptomycin FMT (blue boxes), DSS+Metronidazole FMT (green boxes) and Vancomycin (Violet boxes)-treated mice. h Frequencies IL-10
secreting colonic total CD45+ immune cell populations or gated dendritic cells (CD11c+ ), neutrophils (Cd11b+ Ly6g+ ), Macrophages (Cd11b+ F4/80
+ ), B cells (CD19+ ) and CD4+ T cells isolated from DSS-treated (black boxes), DSS+ untreated FMT (white boxes), DSS+ABX FMT (red boxes), DSS
+ Streptomycin FMT (blue boxes), DSS+Metronidazole FMT (green boxes) and DSS+Vancomycin FMT (Violet boxes)-treated mice. Statistical
signiﬁcance was calculated using a Mann–Whitney test for comparison within two groups or Kruskal–Wallis test with Dunn’s multiple comparison
correction within more than two groups. *P < 0.05, **P < 0.01, ***P < 0.001 were regarded as statistically signiﬁcant. Outliers were detected with Grubb’s
test. Non parametric distributions were represented as median+/− interquartile range. In Box and whiskers plots, centre line represents median; cross,
represents mean; dots represent outliers. In (b–e) UT n= 4; DSS, DSS+Abx FMT n= 5; DSS+ Strepto FMT, DSS+Metro FMT n= 6; DSS+ FMT Vanco
n= 3. In (f–h) UT n= 4; DSS n= 5; DSS+Abx FMT, DSS+ Strepto FMT, DSS+Metro FMT, DSS+ FMT Vanco n= 6
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The resolution of intestinal inﬂammation has been also linked
to the activation and the functional plasticity of CD4+ T cells
from pro-inﬂammatory to tolerogenic/IL-10-producing sub-
types63,66. Upon therapeutic FMT, both CD4+ and iNKT cells
produce IL-10. Importantly, since IL-10 also negatively affects the
proliferative capacity of cells the overall increased availability of
colonic IL-10 might be directly responsible for the reduced pro-
liferative capacity of T cells together with the decreased antigen
presentation by APC, as shown by their reduced levels of MHC-
II.
In this manuscript we show that colonic APC, such as neu-
trophils and macrophages, both recruited in the inﬂamed gut67,68
are also strongly reduced in frequency and absolute number upon
therapeutic FMT. This is in line with ﬁndings showing that
macrophages contribute to IBD pathogenesis and are direct target
of anti-TNF therapy, which induces their apoptosis69 and/or a
regulatory M2 phenotype67.
Finally, we also show that the levels of MHCII and the fre-
quency of MHCII+ professional APC in the colonic lamina
propria are strongly down-regulated upon FMT. Importantly,
colonic HLA-DR expression levels discriminate between healthy,
quiescent and active IBD patients70, conﬁrming a prominent role
of MHCII-dependent antigen presentation in IBD immuno-
pathology. Since IFNγ up-regulates MHCII molecules, the
observed reduction of colonic IFNγ after FMT could explain the
decrease of MHCII surface levels and it might be instrumental for
reducing the presentation of bacterial antigens to CD4+T cells.
In conclusion, we demonstrate that modulation of intestinal
microbiota by FMT during experimental colitis exerts multiple
effects in both adaptive and innate mucosal immune responses.
The restoration of normobiosis, possibly also through cooperative
interactions among commensal species, could be the ﬁrst hint to
simultaneously trigger several immune pathways leading to tol-
erogenic functions of innate and adaptive immune cells that
altogether contribute to the resolution of the inﬂammatory pro-
cesses. Further studies will highlight if deﬁned microbial species
or community-based effects contribute to tolerogenic mechan-
isms in the gut.
These ﬁndings on overall represent an important contribution
toward the elucidation of the complex interplay between the
immune system and the gut microbial ecosystem and are
instrumental for better understanding the immune events
occurring during therapeutic FMT in humans.
Methods
Mice. C57BL/6 mice (Charles River, IT) and CXCR6 EGFP/+mice (B6.129P2-
Cxcr6tm1Litt/J; IMSR_JAX: 005693) background C57BL/6, purchased as GFP/GFP
from JAX, USA, and bred to heterozigosity with C57BL/6 mice) of 8–10 weeks of
age were housed at the IEO animal facility in SPF conditions. Experimental groups
of mice receiving the different FMT treatments were kept in separated cages.
Littermates of same sex and age were randomly assigned to the different experi-
mental groups.
Animal procedures were approved by the Italian Ministry of Health (Auth. 127/
15, 27/13, 913/16, 415/17) and by the OPBA of the European Institute of Oncology,
IEO, Italy.
Experimental colitis models. For the induction of DSS-induced acute colitis, mice
were given 2% (w/v) dextran sodium sulphate (DSS, MW 40 kD; TdB Consultancy)
in their drinking water for 7 days followed by 2 days of recovery. The weight curve
was determined by weighing mice daily. At sacriﬁce, colons were collected, their
length was measured and divided in portions to be ﬁxed in 10% formalin for
histological analyses, snap-frozen for RNA extraction and for lamina propria
mononuclear cells (LPMC) immunophenotyping.
Faecal microbiota transplantation (FMT). FMT was performed through oral
gavage of mucus (ﬁrst day) and faeces (second and third days) preparations from
donor mice. This protocol facilitates the engraftment of the mucus-associated
bacteria. Donor mice were untreated (normobiotic) donors, DSS-treated (dysbio-
tic) or treated with metronidazole (1 g/L), vancomycin (1 g/L), streptomycin (2 g/L)
or a cocktail of the three antibiotics combined in order to deplete distinct taxa of
bacteria. Mucus was scraped from colons, diluted in PBS and administered to
recipients at 1:1 ratio. Faeces were collected, diluted in PBS (50 mg/ml) and
administered to recipients by oral gavage (10 mg/mouse) one day after the end of
acute DSS administration.
For in vivo IL-10R blockade, mice were injected intraperitoneally with 250 µg
InVivoMAb anti-mouse IL-10R (BioXCell, clone 1B1.3 A), or its Isotype
(BioXCell), daily for 4 days starting from one day before FMT treatment.
Murine cell isolation. For LPMC isolation, Peyer’s Patches were removed, colonic
lamina propria lymphocytes (LPL) were isolated via incubation with 5 mM EDTA
at 37 °C for 30 min, followed by further digestion with collagenase IV and DNase at
37 °C for 1 h. Cells were then separated with a Percoll gradient.
In some experiments after isolation cells were re-stimulated in vitro for 3 h with
PMA/Ionomycin in the presence of Brefeldin A for cytokine secretion.
Flow cytometry analysis. Cells were stained with combinations of directly con-
jugated antibodies described in Supplementary Table 3. iNKT cells were identiﬁed
by CXCR6-EGFP expression or mCD1d:PBS57 Tetramer (NIH Tetramer core
facility) staining.
Intracellular staining of cytokines was performed after cells ﬁxtion and
permeabilization with Cytoﬁx/Cytoperm (BD) before addition of the antibodies.
Samples were analysed by a FACSCanto II ﬂow cytometer (BD), gated to exclude
nonviable cells. Data were analysed using FlowJo software (BD). The complete list
of the antibodies and dyes used in the study are described in Supplementary
Table 3.
RT-qPCR of tissue mRNA. Total RNA from colonic tissues was isolated using
TRIZOL and Quick-RNA MiniPrep (ZymoResearch) according to manufacturer’s
speciﬁcations and following the MetaHIT project guidelines. cDNAs were gener-
ated from 1 µg of total RNA with reverse transcription kit (Promega). Gene
expression levels were evaluated by qPCR and normalized to Rpl32 gene expres-
sion. The primer sequences are collected in Supplementary Table 2.
Immunoﬂuorescence. Intestinal samples were ﬁxed overnight in paraformalde-
hyde, L-Lysine pH 7.4 and NaIO4 (PLP buffer). They were then washed, dehy-
drated in 20% sucrose for at least 4 h and included in OCT (Sakura). 10μm-thick
sections were re-hydrated with 0.1 M Tris HCl pH: 7.4 buffer and blocked with
0.3%triton X-100, 2% FBS 0.1 M Tris-HCl buffer. Slides were incubated with the
primary antibody (anti ZO-1 FITC, 1:100) for 2 hrs. Nuclei were counterstained
with DAPI (1:30.000; Roche) and mounted with Vectashield (Vectorlabs).
Histological analysis. Tissue processing was performed with a LEICA PELORIS
processor before parafﬁn embedding71. Murine samples were included using an
automated system (SAKURA Tissue-Tek). After Hematoxylin and Eosin staining,
snapshots of histology were taken using an Aperio CS2 microscope with a scanning
resolution of 50,000 pixels per inch (0.5 µm per pixel with 10x objective and 2.5 µm
per pixel when scanning at ×4). Scoring of disease activity was performed
according to the criteria described in Supplementary Table 1.
Microbiota identiﬁcation. Faeces and mucus scraped from the colon were stored
at −80 °C until the DNA was extracted with G NOME DNA isolation kit (MP)
following the protocol described in72 Partial 16 S rRNA gene sequences were
ampliﬁed using primer pair Probio_Uni and /Probio_Rev, targeting the V3 region
of the 16 S rRNA gene sequence73. The 16S rRNA gene sequencing was performed
using a MiSeq (Illumina) at the DNA sequencing facility of GenProbio srl (www.
genprobio.com)73.
Following sequencing, the obtained individual sequence reads were ﬁltered by
the Illumina software to remove low quality and polyclonal sequences. All Illumina
quality-approved, trimmed and ﬁltered data were exported as.fastq ﬁles. The.fastq
ﬁles were processed using a custom script based on the QIIME software suite74.
Quality control retained sequences with a length between 140 and 400 bp and mean
sequence quality score > 20 while sequences with homopolymers > 7 bp and
mismatched primers were omitted. To calculate downstream diversity measures
(alpha and beta diversity indices, Unifrac analysis), 16S rRNA Operational
Taxonomic Units (OTUs) were deﬁned at ≥ 99 % sequence homology using
uclust75 and OTUs with less than 10 sequences were ﬁltered. All reads were
classiﬁed to the lowest possible taxonomic rank using QIIME74 and a reference
dataset from the SILVA database. Biodiversity of the samples (alpha-diversity) were
calculated with Chao1 and Shannon indexes. Similarities between samples (beta-
diversity) were calculated by unweighted uniFrac76. The range of similarities is
calculated between the values 0 and 1. PCoA representations of beta-diversity were
performed using QIIME 74.
TNBS-induced experimental colitis. For TNBS-induced acute colitis, mice were
rectally challenged with 3 mg of Picrylsulfonic acid (TNBS, MW 293.17 Fluka). The
weight curve was determined by weighing mice daily. At sacriﬁce colons were
collected, their length was measured and divided in portions to be ﬁxed in 10%
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formalin for histological analyses, snap-frozen for RNA extraction and for lamina
propria mononuclear cells (LPMC) immunophenotyping.
Metabolomic analysis. Metabolome extraction, puriﬁcation and derivatization
was carried by means of the MetaboPrep kit (Theoreo srl, Montecorvino Pugliano
[SA], Italy) according to the manufacturer’s instruction.
Two µL samples of the derivatized solution were injected into the GC-MS
system (GC-2010 Plus gas chromatograph coupled to a 2010 Plus single
quadrupole mass spectrometer; Shimadzu Corp., Kyoto, Japan). Chromatographic
separation was achieved with a 30 m 0.25 mm CP-Sil 8 CB fused silica capillary GC
column with 1.00 µm ﬁlm thickness from Agilent (Agilent, J&W Scientiﬁc, Folsom,
CA, USA), with helium as carrier gas. The initial oven temperature of 100 °C was
maintained for 1 min and then raised by 4 °C/min to 320 °C with a further 4 min of
hold time. The gas ﬂow was set to obtain a constant linear velocity of 39 cm/s and
the split ﬂow was set at 1:5. The mass spectrometer was operated in electron impact
(70 eV) in full scan mode in the interval of 35-600 m/z with a scan velocity of 3333
amu/sec and a solvent cut time of 4.5 min. The complete GC program duration was
60 min. Untargeted metabolites were identiﬁed by comparing the mass spectrum of
each peak with the NIST library collection (NIST, Gaithersburg, MD, USA). To
identify metabolites identity, the linear index difference max tolerance was set at
10, while the minimum matching for the NIST library search was set at 85%. The
chromatographic data for PLS-DA analysis were tabulated with one sample per row
and one variable (metabolite) per column. According to MSI level 1 standard77, the
VIP putative metabolites identity was conﬁrmed by means of an independent
analytical standard analysis. The normalization procedures consisted of data
transformation and scaling. Data transformation was made by generalized log
transformation and data scaling by autoscaling (mean-centered and divided by
standard deviation of each variable).
Metabolomics data analysis. Partial least square discriminant analysis (PLS-DA) 78
was performed on Internal Standard peak area 79 normalized chromatogram using
R (Foundation for Statistical Computing, Vienna, Austria). Mean centering and
unit variance scaling was applied for all analyses. Classes separation was archived
by PLS-DA, which is a supervised method that uses multivariate regression tech-
niques to extract, via linear combinations of original variables (X), the information
that can predict class membership (Y). PLS regression was performed using the plsr
function included in the R pls package80. Classiﬁcation and cross-validation was
performed using the corresponding wrapper function included in the caret pack-
age. A permutation test was performed to assess the signiﬁcance of class dis-
crimination. In each permutation, a PLS-DA model was built between the data (X)
and the permuted class labels (Y) using the optimal number of components
determined by cross validation for the model based on the original class assign-
ment. Variable Importance in Projection (VIP) scores were calculated for each
component. A VIP is a weighted sum of squares of the PLS loadings, taking into
account the amount of explained Y-variation in each dimension.
To identify the most meaningful changes in two conditions, the volcano plot
was used. This combines a measure of statistical signiﬁcance from a statistical test
(p value) with the magnitude of the change, enabling quick visual identiﬁcation of
those data points (metabolites) that display large magnitude changes that are also
statistically signiﬁcant. The volcano plots were constructed by plotting the negative
log of the p value on the y axis. This results in data points with low p values (highly
signiﬁcant) appearing toward the top of the plot. The x axis was the log of the fold
change between the two conditions. The log of the fold change is used so that
changes in both directions appear equidistant from the center. Plotting points
results in two regions of interest in the plot: those points that are found toward the
top of the plot that are far to either the left- or right-hand sides. These represent
values that display large magnitude fold changes (hence being left or right of
center) as well as high statistical signiﬁcance (hence being toward the top).
In vitro T-cell activation assay. Colonic lamina propria and mesenteric lymph
node leukocytes were collected from untreated mice. 2 × 106 cells were plated and
exposed to 0.05 mg of bacteria (wet weight) derived from faeces of untreated, DSS-
treated or FMT-treated mice at the time of sacriﬁce. Gentamycin (50 µg/ml) and a
cocktail of antibiotics (P/S) were added after 2 h of incubation. The cells were left in
culture for 96 h. In some experiments, anti-MHCII blocking antibody (clone M5/
114.15.2, TONBO) was added at a ﬁnal concentration of 10 µg/ml. At the end of
the experiment cells were analysed with ﬂow cytometry. Their viability was checked
with Zombie Yellow™ Fixable Viability Kit (Biolegend).
Tissue ELISA of murine IL-10. Colonic tissues were homogenized in 300 µl RIPA
Buffer (Cell Signaling Technology) supplemented with Phosphatase inhibitors
(Sigma) and Protease inhibitors (Complete Ultra tablets, Roche). The samples were
then incubated at 4 °C for 30 min under slow rotation and then centrifuged at
13,000 r.p.m. (16.2 × g) for 15 min at 4 °C. The supernatant was quantiﬁed at the
NanoDrop with Bradford Assay (BioRad). mIIL-10 was measured on 6.25 µg of
lysate using the ELISA assay (Puriﬁed anti-mouse IL-10 and Biotin anti-mouse IL-
10, Biolegend) performed following manufacturer’s instructions.
Faecal bacteria plating. One faecal pellet from each mouse was smashed, ﬁltered
with 100 µm nylon cell strainer and resuspended in 1 mL of sterile PBS. A con-
centration of 200 µL were then plated on Chocolate II Agar plates (BD) and grown
at 37 °C under aerobic conditions overnight or in anaerobic conditions for 48 h.
Quantiﬁcation and statistical analysis. Statistical analysis was performed with
GraphPad Prism 5 (GraphPad Software). Statistical signiﬁcance was calculated
using a Mann–Whitney test for comparison within two groups or Kruskal–Wallis
test with Dunn’s multiple comparison correction within more than two groups.
*P < 0.05, **P < 0.01, ***P < 0.001 were regarded as statistically signiﬁcant. Outliers
were detected with Grubb’s test. Non parametric distributions were represented as
median+/− interquartile range.
Data availability
16S rRNA raw data for Figs. 2a–f, 3a, b, 4d, f, 8b, e and Supplementary 4a, b, 5a, c,
are available in SRA Online Repository associated to BioProject PRJNA494680.
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